Weedkiller ingredient widely used in US can damage organs and gut bacteria, research shows
The ingredient, diquat, is widely employed in the US as a weedkiller in vineyards and orchards, and is increasingly sprayed elsewhere as the use of controversial herbicide substances such as glyphosate and paraquat drops in the US.
But the new piece of data suggests diquat is more toxic than glyphosate, and the substance is banned over its risks in the UK, EU, China and many other countries. Still, the EPA has resisted calls for a ban, and Roundup formulas with the ingredient hit the shelves last year.
Related: 'We thought we'd got the numbers wrong': how a pristine lake came to have the highest levels of 'forever chemicals' on record
'From a human health perspective, this stuff is quite a bit nastier than glyphosate so we're seeing a regrettable substitution, and the ineffective regulatory structure is allowing it,' said Nathan Donley, science director with the Center For Biological Diversity, which advocates for stricter pesticide regulations but was not involved in the new research. 'Regrettable substitution' is a scientific term used to describe the replacement of a toxic substance in a consumer product with an ingredient that is also toxic.
Diquat is also thought to be a neurotoxin, carcinogen and linked to Parkinson's disease. An October analysis of EPA data by the Friends of the Earth non-profit found it is about 200 times more toxic than glyphosate in terms of chronic exposure.
Bayer, which makes Roundup, faced nearly 175,000 lawsuits alleging that the product's users were harmed by the product. Bayer, which bought Monsanto in 2018, reformulated Roundup after the International Agency for Research on Cancer classified glyphosate as a possible carcinogen.
The new review of scientific literature in part focuses on the multiple ways in which diquat damages organs and gut bacteria, including by reducing the level of proteins that are key pieces of the gut lining. The weakening can allow toxins and pathogens to move from the stomach into the bloodstream, and trigger inflammation in the intestines and throughout the body. Meanwhile, diquat can inhibit the production of beneficial bacteria that maintain the gut lining.
Damage to the lining also inhibits the absorption of nutrients and energy metabolism, the authors said.
The research further scrutinizes how the substance harms the kidneys, lungs and liver. Diquat 'causes irreversible structural and functional damage to the kidneys' because it can destroy kidney cells' membranes and interfere with cell signals. The effects on the liver are similar, and the ingredient causes the production of proteins that inflame the organ.
Meanwhile, it seems to attack the lungs by triggering inflammation that damages the organ's tissue. More broadly, the inflammation caused by diquat may cause multiple organ dysfunction syndrome, a scenario in which organ systems begin to fail.
The authors note that many of the studies are on rodents and more research on low, long-term exposure is needed. Bayer did not immediately respond to a request for comment.
Despite the risks amid a rise in diquat's use, the EPA is not reviewing the chemical, and even non-profits that push for tighter pesticide regulations have largely focused their attention elsewhere.
Donley said that was in part because US pesticide regulations are so weak that advocates are tied up with battles over ingredients like glyphosate, paraquat and chlorpyrifos – substances that are banned elsewhere but still widely used here. Diquat is 'overshadowed' by those ingredients.
'Other countries have banned diquat, but in the US we're still fighting the fights that Europe won 20 years ago,' Donley said. 'It hasn't gotten to the radar of most groups and that really says a lot about the sad and sorry state of pesticides in the US.'
Some advocates have accused the EPA of being captured by industry, and Donley said US pesticide laws were so weak that it was difficult for the agency to ban ingredients, even if the will exists. For example, the agency banned chlorpyrifos in 2022, but a court overturned the decision after industry sued.
Moreover, the EPA's pesticides office seems to have a philosophy that states that toxic pesticides are a 'necessary evil', Donley said.
'When you approach an issue from that lens there's only so much you will do,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
24 minutes ago
- Associated Press
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics' live webcast of the Phase 2 APEX Part A results will begin on Monday, July 7th at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company's website at A replay of the webcast will be available following the call. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care. For more information, please visit Investor Contact: Noel Kurdi VP, Investor Relations Apogee Therapeutics, Inc. [email protected] Media Contact: Dan Budwick 1AB [email protected]
Yahoo
38 minutes ago
- Yahoo
The Gas Station Chain That Offers Frozen House-Made Energy Drinks
It seems like everyone's gotten into the energy drink market these days, from Monster, Ghost, and Celsius, to the OG, Red Bull. Some might say that the market is oversaturated, but Wawa saw that market share and asked, "What if energy drinks could also be slushies?" And thus, it created Rechargers. These brightly-colored, frozen, house-made energy drinks are perfect for those times when you can't decide between a frozen margarita and a Mountain Dew Kickstart. Because really, you shouldn't have to as long as you're near a Wawa. If you're not from the Mid-Atlantic or lower East Coast area of the U.S., you might not know that Wawa, a beloved convenience store, is much more than a simple gas station. From fresh house-brand coffee to substantial made-to-order meatball hoagies, Wawa truly walks the line between convenience store and café, and its line of energy drinks, which were released in 2023, are another fan favorite on its lengthy lineup of road-ready offerings. What sets Wawa's line of drinks apart from, say, a typical can of Bang, where every sip is identical, is that the chain offers what seems like endless ways to customize your drink. Read more: Store-Bought Lemonade, Ranked From Worst To Best Energy drink lovers know that no matter the brand, the flavors can leave a lot to be desired. Even if you've grown to love the medicinal taste of Red Bull, there's no denying that it's nice to have some flavor options to mask the taste of caffeine and supplements like taurine, B vitamins, and ginseng. This is where Wawa's Rechargables really come in clutch. You can choose from more than 10 different base flavors like Sunset Punch (mango lemonade), or The Mermaid (blue raspberry, passionfruit, and dragonfruit). Each drink comes standard with 75 to 150 milligrams of caffeine, with an option to add a "boost" of energy (an additional 37 to 111 milligrams of caffeine), immunity (vitamins and minerals including vitamin C, vitamin D, vitamin B3, and zinc), or protein (100% whey). You can also add Sour Cherry Popping Bubbles for an extra fee. In addition to sizing (16 to 32 ounces), your drink can be served iced instead of frozen, and there are options for less sugar or zero sugar. Admittedly, it is all a lot of decision making, and you need to keep your wits about you to order a soft pretzel, a delicacy in Eastern Pennsylvania, so once you've figured out your ideal Recharger combo, be sure to save it as a favorite in the Wawa app so that ordering a little get-up-and-go is that much easier next time. Read the original article on Chowhound.
Yahoo
44 minutes ago
- Yahoo
Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health
SHELTON, Conn., July 06, 2025 (GLOBE NEWSWIRE) -- Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EGT Synbio, headquartered in Shanghai, China, has successfully completed two human clinical trials evaluating the effects of oral L-ergothioneine ( on skin health. Abinopharm, Inc. is the exclusive U.S. collaborator and distributor for EGT Synbio's premium L-ergothioneine product, L-Ergothioneine was first isolated in 1909 by French chemist Charles Tanret from the ergot fungus (Claviceps purpurea), giving the compound its name: 'ergo' from ergot and 'thioneine' denoting a sulfur-containing compound. Although ergothioneine is found in many plants and animals, it cannot be synthesized by them and must be acquired from fungi—especially mushrooms—and certain bacteria. In humans, dietary intake of mushrooms, particularly shiitake, maitake, and oyster mushrooms, which contain 10–13 mg/100 g dry weight, is the main source. For many years, the biological significance of ergothioneine remained obscure. This changed in 2005 when Professor Günther Gündemann discovered the ergothioneine-specific transporter OCTN1 (SLC22A4), which facilitates its accumulation in nearly all human tissues, particularly in the bone marrow, liver, kidneys, red blood cells, brain, eyes, and skin. Professor Barry Halliwell, a pioneer in the study of reactive oxygen species (ROS) and oxidative stress, later identified ergothioneine as one of the most potent natural antioxidants. He demonstrated its role in mitigating oxidative damage and inflammation—factors contributing to conditions such as neurodegenerative diseases (e.g., Alzheimer's, Parkinson's), cardiovascular disorders, and liver disease. Studies have also shown that ergothioneine has high bioavailability, a long half-life in the human body, and offers cellular protection—particularly within mitochondria—thereby helping maintain cognitive function, reduce inflammation, and support healthy longevity. In 2018, renowned biochemist Professor Bruce Ames proposed that ergothioneine be classified as a 'longevity vitamin'—a micronutrient not essential for immediate survival but vital for long-term health and healthy aging. He suggested that low levels of ergothioneine may accelerate aging and increase the risk of chronic diseases. A Nutrient for Radiant and Resilient Skin Ergothioneine is a multifunctional skincare nutrient known for its antioxidant power, anti-inflammatory effects, and UV protection. It protects skin cell components—lipids, DNA, and proteins—from oxidative damage and premature aging, helps prevent photoaging (e.g., sunspots, collagen breakdown), soothes redness and inflammation (e.g., acne, eczema, sensitive skin), promotes even skin tone and radiance, supports collagen synthesis and elasticity, and enhances skin hydration. While ergothioneine has been used topically in cosmetic products for years, a 2024 Japanese clinical study confirmed its effectiveness as an oral "beauty-from-within" ingredient. In this study, participants who consumed a hiratake (oyster mushroom) tablet containing 25 mg of ergothioneine daily experienced significant improvements in facial skin moisture and overall skin condition (Frontiers in Medicine, 2024). New Clinical Results with Abinopharm and EGT Synbio now report results from two human clinical trials evaluating the efficacy of L-ergothioneine for skin health: Open-label trial in China (2023):Nineteen healthy participants consumed 25 mg of daily for four weeks. Dermatological assessments using the VISIA imaging system revealed visible improvements in skin pores, wrinkles, UV spots, brown spots, and porphyrins. No adverse effects were reported. Results were published in the American Journal of Biomedical Science & Research (DOI: 10.34297/AJBSR.2023.20.002779). Double-blind, placebo-controlled trial in Japan (2024):Conducted by the Japan Clinical Trial Association (JACTA), this 8-week study enrolled 66 healthy women aged 35 to 59. Participants received 30 mg of daily. Skin parameters including brightness, tone, melanin, erythema, gloss, elasticity, and spots were measured using scientific instruments and questionnaires. After 8 weeks, participants showed statistically significant improvements (p < 0.01) in brightness, elasticity, melanin levels, erythema, wrinkles, and skin gloss. No significant adverse events were reported. Details available at - and Safety Commitment is produced using a patented full enzymatic fermentation process (EP 4520819A1) under strict cGMP standards. It has been granted (Generally Recognized as Safe) status, NSF GMP certification, HACCP compliance, and HALAL certification. The product adheres to ICH quality guidelines, with purity and optical purity >99.9%. All impurities, heavy metals, and microbial levels are controlled within USP limits. About EGT SynbioEGT Synbio pioneers biological solutions for anti-aging. Its scientific team develops clinically validated compounds, including the premium L-Ergothioneine—an odorless, stable crystal ingredient used by global brands and certified by U.S. GRAS, EU Novel Food, and NSF. In 2024, EGT Synbio launched EquoPro™ (S)-Equol and Spermidine Hydrochloride, expanding its offerings in dietary supplements, skincare, and pharmaceuticals. Its ingredients are now widely used across functional foods, luxury beauty, and medical-grade nutrition. About Abinopharm, Inc. is a U.S.-based nutritional and biopharmaceutical company focused on developing, manufacturing, and commercializing premium health products in the U.S. and globally. Its nutritional division specializes in longevity ingredients, partnering with leading academic and industry experts. The company's NMN ingredient (AbinoNutra®NMN) holds Self-Affirmed GRAS status and has been clinically validated in collaboration with Professor Andrea Maier. Other flagship ingredients include L-Ergothioneine ( Fisetin (BeFisetin®), Urolithin A, CaAKG, Spermidine ( S-Equol (EquoPro™), and Hydroxytyrosol. Abinopharm offers regulatory support (e.g., GRAS, NPN), as well as private-label solutions for supplements made in the U.S., Canada, and Europe. Contact:Public ServiceAbinopharm, A photo accompanying this announcement is available at in to access your portfolio